Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III

FEBS Journal

Volumn 277, Issue 2, 2010, Pages 441-452

  Roy, P ^a   Reavey, E ^a   Rayne, M ^a   Roy, S ^a   Abed El Baky, M ^a   Ishii, Y ^b   Bartholomew, C ^a  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Carbonic anhydrase III; Evi1; H2O2

Indexed keywords

CARBONATE DEHYDRATASE III; CASPASE 3; EVI1 PROTEIN; HYDROGEN PEROXIDE; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CATALYSIS; CELL PROTECTION; ENZYME ACTIVITY; ENZYME SUBSTRATE; ENZYME SYNTHESIS; FIBROBLAST; GENE OVEREXPRESSION; LEUKEMIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RAT; REPORTER GENE; SOLID TUMOR; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CARBONIC ANHYDRASE III; CASPASE 3; CELL LINE; DNA PRIMERS; DNA-BINDING PROTEINS; DOWN-REGULATION; HYDROGEN PEROXIDE; MICE; PACLITAXEL; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENES; RATS; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION;

RATTUS;

EID: 74549126102     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2009.07496.x     Document Type: Article

References (43)

1. Weiser R (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396, 346 357.
2. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y Hirai H (2000) The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19, 2958 2968.
3. Buonamici S, Li D, Mikhail FM, Sassano A, Platanias LC, Colamonici O, Anastasi J Nucifora G (2005) EVI1 abrogates interferon-alpha response by selectively blocking PML induction. J Biol Chem 280, 428 436.
4. Liu Y, Chen L, Ko TC, Fields AP Thompson EA (2006) Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 25, 3565 3575.
5. Shackelford D, Kenific C, Blusztajn A, Waxman S Ren R (2006) Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res 66, 11360 11369.
6. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T Morishita K (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24, 1976 1987.
7. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN Mucenski ML (1997) The Evi1 proto-oncogene is required at midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 65, 55 70.
8. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG Ihle JN (1988) Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54, 831 840.
9. Bartholomew C, Kilbey A, Clark AM Walker M (1997) The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene 14, 569 577.
10. Delwel R, Funabiki T, Kreider BL, Morishita K Ihle JN (1993) Four of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol 13, 4291 4300.
11. Funabiki T, Kreider BL Ihle JN (1994) The carboxyl domain of zinc fingers of the Evi-1 myeloid transforming gene binds a consensus sequence of GAAGATGAG. Oncogene 9, 1575 1581.
12. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K Hirai H (1998) The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 394, 92 96.
13. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K Hirai H (2001) The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 97, 2815 2822.
14. Ames BN, Shigenaga MK Hagen TM (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 90, 7915 7922.
15. Wu WS (2006) The signalling of ROS in tumor progression. Cancer Metastasis Rev 25, 695 705.
16. Wistrand PJ (2002) Carbonic anhydrase III in liver and muscle of male rats. Purification and properties. Ups J Med Sci 107, 77 88.
17. Lehtonen J, Shen B, Vihinen M, Casini A, Scozzafava A, Supuran CT, Parkkila AK, Saarnio J, Kivelä AJ, Waheed A et al. (2004) Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 279, 2719 2727. (Pubitemid 38114261)
18. Carter ND, Lönnerholm G, Meyerson BJ Wistrand PJ (2001) Androgen-linked control of carbonic anhydrase III expression occurs in rat perivenous hepatocytes; an immunocytochemical study. Ups J Med Sci 106, 67 76.
19. Parkkila S, Halsted CH, Villanevva JA, Väänänen HK Niemelä O (1999) Expression of testosterone-dependent enzyme, carbonic anyhdrase III and oxidative stress in experimental alcoholic liver disease. Dig Dis Sci 44, 2205 2213.
20. Raisanen SR, Lehenkari P, Tasana M, Rahkila P, Harkonen PL Väänänen HK (1999) Carbonic anhydrase III protects cells from hydrogen peroxide- induced apoptosis. FASEB J 13, 513 522.
21. Ishii Y, Akazawa D, Aoki Y, Yamada H Oguri K (2005) Suppression of carbonic anhydrase III mRNA level by an aryl hydrocarbon receptor ligand in primary cultured hepatocytes of rat. Biol Pharm Bull 28, 1087 1090.
22. Kim G, Lee TH, Wetzel P, Geers C, Robinson MA, Myers TG, Owens JW, Wehr NB, Eckhaus MW, Gros G et al. (2004) Carbonic anhydrase III is not required in the mouse for normal growth, development, and life span. Mol Cell Biol 24, 9942 9947.
23. Zimmerman UJ, Wang P, Zhang X, Bogdanovich S Forster R (2004) Anti-oxidative response of carbonic anhydrase III in skeletal muscle. IUBMB Life 56, 343 347.
24. Khanna-Gupta A, Lopingco MC, Savinelli T, Zibello T, Berliner N Perkins AS (1996) Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3. Oncogene 12, 563 569.
25. Alzuherri H, McGilvray R, Kilbey A Bartholomew C (2006) Conservation and expression of a novel alternatively spliced Evi1 exon. Gene 384, 154 162.
26. Sood R, Talwar-Trikha A, Chakrabarti SR Nucifora G (1999) MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia 13, 348 357.
27. Kharbanda KK, Vigneswara V, McVicker BL, Newlaczyl AU, Bailey K, Tuma D, Ray DE Carter WG (2009) Proteomics reveal a concerted upregulation of methionine metabolic pathway enzymes, and downregulation of carbonic anhydrase-III, in betaine supplemented ethanol-fed rats. Biochem Biophys Res Commun 381, 523 527.
28. Zoll J, Ponsot E, Dufour S, Doutreleau S, Ventura-Clapier R, Vogt M, Hoppeler H, Richard R Flück M (2006) Exercise training in normobaric hypoxia in endurance runners. III. Muscular adjustments of selected gene transcripts. J Appl Physiol 100, 1258 1266.
29. Tweedie S, Morrison K, Charlton J Edwards YH (1991) CAIII a marker for early myogenesis: analysis of expression in cultured myogenic cells. Somat Cell Mol Genet 17, 215 228.
30. Palmer S, Brouillet JP, Kilbey A, Fulton R, Walker M, Crossley M Bartholomew C (2001) Evi-1 transforming and repressor activities are mediated by CtBP co-repressor proteins. J Biol Chem 276, 25834 25840.
31. Spensberger D Delwel R (2008) A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 582, 2761 2767.
32. Vinatzer U, Taplick J, Seiser C, Fonatsch C Wieser R (2001) The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase. Br J Haematol 114, 566 573.
33. Yatsula B, Lin S, Read AJ, Poholek A, Yates K, Yue D, Hui P Perkins AS (2005) Identification of binding sites of EVI1 in mammalian cells. J Biol Chem 280, 30712 30722.
34. Laricchia-Robbio L, Premanand K, Rinaldi CR Nucifora G (2009) EVI1 impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 69, 1633 1642.
35. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S Nucifora G (2007) Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer Res 67, 5658 5666.
36. Laricchia-Robbio L, Fazzina R, Li D, Rinaldi CR, Sinha KK, Chakraborty S Nucifora G (2006) Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells. Mol Cell Biol 26, 7658 7666.
37. Chi Y, Senyuk V, Chakraborty S Nucifora G (2003) EVI1 promotes cell proliferation by interacting with BRG1 and blocking the repression of BRG1 on E2F1 activity. J Biol Chem 278, 49806 49811.
38. Nucifora G, Laricchia-Robbio L Senyuk V (2006) EVI1 and hematopoietic disorders: history and perspectives. Gene 368, 1 11.
39. Kuo WH, Chiang WL, Yang SF, Yeh KT, Yeh CM, Hsieh YS Chu SC (2003) The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci 73, 2211 2223.
40. Kuo WH, Yang SF, Hsieh YS, Tsai CS, Hwang WL Chu SC (2005) Differential expression of carbonic anhydrase isoenzymes in various types of anemia. Clin Chim Acta 351, 79 86.
41. Wigler M, Silverstein S, Lee LS, Pellicer A, Cheng Y Axel R (1977) Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 1, 223 232.
42. Livak KJ Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402 408.
43. Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC Thomas M (1983) Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 130, 1910 1917.